Amgen Inc (AMGN · NASDAQ)
AMGN · MARKET VIEW
Market view · as of Jun 29, 2026
Revenue (TTM)
$37.22B
+5.8% YoY
Gross margin
71.4%
EPS (latest q)
$5.15
vs $4.77 est · beat
52-wk position
77.6%
-7.0% vs 52w high · +6.5% 1mo
Price (last ~year)
Amgen Inc. faces operational headwinds following the FDA approval of a competing thyroid eye disease therapy and a voluntary recall of nearly one million bottles of Corlanor and Sensipar tablets. Despite these developments, the company maintains a $193.39 billion market capitalization, reporting $8.62 billion in revenue and $1.82 billion in net income for the first quarter of 2026. Shares have risen 6.5% over the last month to trade at $358.33, supported by a 3.4x debt-to-EBITDA ratio and year-over-year revenue growth of 5.8%.
Valuation
- Market cap
- $193.39B
- P/E
- 24.94
- PEG
- 1.964
- P/B
- 21.04
- P/S
- 5.2
- EV/EBITDA
- 14.32
- Beta
- 0.416
- Analyst target
- $352.77
Quality & returns
- Gross margin
- 71.4%
- Operating margin
- 33.8%
- Profit margin
- 21.0%
- ROE
- 101.3%
- ROA
- 8.3%
Price movement
- Last
- $358.33
- 1-month
- +6.5%
- 3-month
- +2.6%
- RSI (14)
- 56
- vs SMA200
- +8.7%
- 52-wk position
- 77.6% -7.0% vs high
Quarterly trajectory
Revenue by quarter (oldest → newest)
| Quarter | Revenue | Op income | Net income | EBITDA |
|---|---|---|---|---|
| 2026-03-31 | $8.62B | $2.67B | $1.82B | $3.86B |
| 2025-12-31 | $9.90B | $3.94B | $1.33B | $3.30B |
| 2025-09-30 | $9.56B | $2.53B | $3.22B | $5.91B |
| 2025-06-30 | $9.17B | $2.64B | $1.43B | $3.62B |
Recent news
- Neutral FDA Approves Viridian’s Thyroid Eye Disease Drug, Competitor to a Blockbuster Amgen Med · 2026-06-28
- Somewhat-Bearish Amgen Recalls Corlanor and Sensipar Tablets Over Foreign Substance Risk - News and Statistics · 2026-06-28
- Somewhat-Bullish Fate Therapeutics Stock Pops As FT836 Cancer Data Impress Traders · 2026-06-28
- Neutral Janney Montgomery Scott LLC Decreases Stake in Amgen Inc. $AMGN · 2026-06-28
- Somewhat-Bullish Nicholas Wealth LLC. Takes $1.16 Million Position in Amgen Inc. $AMGN · 2026-06-28
- Somewhat-Bullish Amgen Inc. $AMGN Shares Bought by Pictet Asset Management Holding SA · 2026-06-28
Sources this view read
- fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
- filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
- earnings Reported earnings history (Alpha Vantage EARNINGS)
- prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)